Newron Pharmaceuticals Valuation Multiples

Newron Pharmaceuticals Overview

About Newron Pharmaceuticals

Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.

Founded

1999

HQ

Employees

22

Website

newron.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $29M

EBITDA: $2M

EV

$448M

Valuation Multiples

Multiples.vc

Start free trial

Newron Pharmaceuticals Financials

Newron Pharmaceuticals reported last 12-month revenue of $29M and EBITDA of $2M.

In the same LTM period, Newron Pharmaceuticals generated $29M in gross profit, $2M in EBITDA, and had net loss of ($14M).

Newron Pharmaceuticals P&L

In the most recent fiscal year, Newron Pharmaceuticals reported revenue of $23M and EBITDA of ($5M).

Newron Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Newron Pharmaceuticals Stock Performance

Newron Pharmaceuticals has current market cap of $437M, and enterprise value of $448M.

Newron Pharmaceuticals' stock price is $20.99.

Newron Pharmaceuticals Valuation Multiples

Newron Pharmaceuticals trades at 15.3x EV/Revenue multiple, and 210.6x EV/EBITDA.

Newron Pharmaceuticals Financial Valuation Multiples

As of April 18, 2026, Newron Pharmaceuticals has market cap of $437M and EV of $448M.

Equity research analysts estimate Newron Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Newron Pharmaceuticals has a P/E ratio of (31.8x).

Newron Pharmaceuticals Margins & Growth Rates

Newron Pharmaceuticals' revenue in the last 12 month grew by 60%.

Newron Pharmaceuticals' revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $1.3M for the same period.

Newron Pharmaceuticals' rule of 40 is 148% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Newron Pharmaceuticals' rule of X is 307% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Newron Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Newron Pharmaceuticals M&A Activity

Newron Pharmaceuticals acquired XXX companies to date.

Last acquisition by Newron Pharmaceuticals was on XXXXXXXX, XXXXX. Newron Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Newron Pharmaceuticals Investment Activity

Newron Pharmaceuticals invested in XXX companies to date.

Newron Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Newron Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).